Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 5 versions Re-verified since May 17, 2023, no change to tracked fieldsv28-v32
  2. Primary and study completion dates: Jan 2022 to Jan 2032v27
  3. Site contact updatedv26
  4. Site contact updatedv25
  5. Site contact updatedv24
Show 22 earlier versionsHide 22 earlier versions
  1. Study completion date: Jan 2022
    • Site contact updated
    v23
  2. Site contact updatedv22
  3. Enrollment target: 500 to 2000
    • Primary endpoint revised
    • Eligibility criteria expanded, about 3 words
    v21
  4. Site contact updatedv20
  5. 3 versions Re-verified since Feb 14, 2013, no change to tracked fieldsv17-v19
  6. Phase: Not applicable to Not specified
    • Enrollment target: 300 to 500
    • Site contact updated
    v16
  7. 3 versions Re-verified since Aug 19, 2010, no change to tracked fieldsv13-v15
  8. Site contact updatedv12
  9. Site contact updatedv11
  10. Site contact updatedv10
  11. Primary completion date: Jan 2022
    • Site contact updated
    • Eligibility criteria expanded, about 1 word
    v9
  12. Eligibility criteria revisedv8
  13. Re-verified, no change to tracked fieldsv7
  14. Eligibility criteria revised
    • Study site revised
    v6
  15. Site contact updatedv5
  16. Re-verified, no change to tracked fieldsv4
  17. Start date: Jan 2002
    • Eligibility criteria expanded, about 13 words
    • Study title expanded, about 4 words
    v3
  18. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
Trial Details
NCT Number NCT00349830
Lead Sponsor Stanford University
Conditions
(from sponsor)		 Carcinomas (Including Squamous Cell and Adenocarcinoma), Neoplasms
Related terms Adenocarcinoma, Carcinoma, Neoplasms
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov